Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

699 - Feasibility of dose-dense doxorubicin and cyclophosphamide (ddAC) followed by taxane (T) in Japanese women with early breast cancer: A retrospective study


20 Dec 2015


Poster presentation 2


Jun Masuda


Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519


J. Masuda1, Y. Ozaki2, H. Nakajima3, R. Oki1, M. Uchiyama1, S. Koganemaru1, T. Ogura4, N. Tamura4, Y. Miura1, Y. Tanabe1, D. Miura4, H. Kawabata4, T. Takano1

Author affiliations

  • 1 Dept. Of Medical Oncology, Toranomon Hospital, 105-8470 - Tokyo/JP
  • 2 Dept. Of Medical Oncology, Toranomon Hospital, Tokyo/JP
  • 3 Dept. Of Medical Oncology, Toranomon Hospital, 105-0001 - Tokyo/JP
  • 4 Dept. Of Breast And Endocrine Surgery, Toranomon Hospital, 105-8470 - Tokyo/JP


Abstract 699


Since in Japan pegfilgrastim was approved as the first G-CSF indicated for prophylactic use in many cancers including breast cancer in September 2014, ddAC (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 on day 1 and pegfilgrastim 3.6 mg/body on day 2 every 2 weeks for 4 cycles) followed by T, one of the global standard regimens for early breast cancer, became available. The goal of this study is to examine the feasibility and efficacy of ddAC-T in Japanese women with early breast cancer.


We retrospectively reviewed data of consecutive patients with early breast cancer (stage I-III), who received ddAC-T or FEC-T (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 500 mg/m2, every 3 weeks for 4 cycles followed by T) as neoadjuvant or adjuvant chemotherapy in our institute between January 2014 and August 2015. Primary endpoints were adverse events (AEs), and secondary endpoints were completion rate, relative dose intensity (RDI) and pathological complete response (pCR) rate.


Eighty-one patients were included in this analysis. Twenty-three patients received ddAC-T (mean age 45, range 36-68) and 58 patients received FEC-T (mean age 49, range 27-70). Stage I patients were 1 (4.3%) in ddAC group and 7 (12.1%) in FEC group, respectively, stage II patients were 14 (60.9%) and 36 (62.1%), respectively, and stage III patients were 8 (34.8%) and 15 (25.8%), respectively. The treatment-related AEs of grade 3 or 4 were as below: neutropenia (0 [0%] in ddAC group and 24 [41.4%] in FEC group), anemia (1 [4.3%] and 1 [1.7%], respectively), pneumonia (2 [8.7%] and 0 [0%], respectively), febrile neutropenia (FN) (0 [0%] and 2 [3.4%], respectively). The grade 1 or 2 fever occurred in 5 (21.7%) of ddAC group and 10 (17.2%) of FEC group. The completion rate was 91.3% in ddAC group, 93.1% in FEC group. RDI in ddAC group and FEC group was 97.8% and 96.6%, respectively. The grade 3 pneumonia in two patients in ddAC group was confirmed as bacterial pneumonia in one and Pneumocystis pneumonia in the other and improved with antibiotics. Updated feasibility and efficacy data will be presented at the meeting.


Dose-dense AC-T is feasible in Japanese women with early breast cancer.

Clinical trial identification

No identification.


T. Takano: honoraria from Kyowa Hakko Kirin. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings